BioCentury
ARTICLE | Financial News

IPF data drives FibroGen to all-time high

August 8, 2017 9:49 PM UTC

On Tuesday, FibroGen Inc. (NASDAQ:FGEN) touched an all-time high of $51.70 before closing up $16.10 (48%) to $49.50 following the release of data late Monday from a Phase II trial of pamrevlumab (FG-3019) to treat idiopathic pulmonary fibrosis.

The human mAb against connective tissue growth factor (CTGF) met the primary endpoint of improving forced vital capacity (FVC) percent predicted from baseline to week 48 vs. placebo (see BioCentury Extra, Aug 7)...

BCIQ Company Profiles

FibroGen Inc.